Skip to main content
Clinical Trials/CTRI/2022/12/048583
CTRI/2022/12/048583
Not yet recruiting
Phase 3

Efficacy of Corticosteroid Therapy in SevereCommunity Acquired Pneumonia

GOVERNMENT MEDICAL COLLEGE AND HOSPITA0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
GOVERNMENT MEDICAL COLLEGE AND HOSPITA
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
GOVERNMENT MEDICAL COLLEGE AND HOSPITA

Eligibility Criteria

Inclusion Criteria

  • 1\. Age more than 18year.
  • 2\. Patients have clinical symptoms suggesting community acquired pneumonia (cough,
  • fever, pleuritic chest pain and/or shortness of breath)
  • 3\. Patient who will be diagnosed as a case of severe community acquired pneumonia as per the
  • criteria ATS IDSA 2007
  • 4\. Those who will give consent for study.

Exclusion Criteria

  • 1\. Immunocompromised patients i.e. HIV infection, neutropenic patients(1000Ã?109
  • cell transplant recipients, patients on immunosuppressive treatment other than
  • corticosteroid, patients of leukemia/lymphoma, chronic liver disease, chronic kidney
  • disease, coronary artery disease and/ or chronic heart failure.
  • 2\. Clinical suspicion of Tuberculosis
  • 3\. Gastrointestinal bleeding in past three months
  • 4\. Conditions requiring adjunctive long\-term corticosteroid therapy (with an equivalent dose
  • of Inj methylprednisolone 1mg/kg/d or more)
  • 5\. Patients with pneumonia secondary to aspiration, hospital\-acquired infection, prior
  • treatment in ICU or receipt of mechanical ventilation.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Effectiveness of corticosteroid injection in treatment of trigger fingers: a double blinded randomized clinical trialTrigger finger (stenosing tenosynovitis) is one of the most common conditions seen by hand surgeons,Although not a severe disease, trigger fingers give disabling complaints in performance of work and ADL activities. The triggering is caused by a size mismatch between the first annular pulley (A1) and the corresponding flexor tendon sheath, but the precise etiology still remains unclear.2-4 Most often, trigger fingers do not resolve spontaneously and need some kind of treatment.Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2020-002285-14-NLJEROEN BOSCH HOSPITA300
Not yet recruiting
Not Applicable
ocal steroids for triggerfingers
NL-OMON26599Jeroen Bosch Hospital,300
Completed
Phase 4
Effectiveness of corticosteroid injection in treatment of trigger fingers: a double blinded randomized clinical trialtenosynovitistriggerfinger10043237
NL-OMON54114Jeroen Bosch Ziekenhuis300
Completed
Not Applicable
Efficacy of acute treatment with steroid in patients with vestibular neuritisvestibular neuritis
JPRN-UMIN000022515Monistry of Education, Culture, Sports Science and Technology240
Recruiting
Not Applicable
Efficacy and safety of corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a prospective randomized multicenter clinical trialanti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis/clinically amyopathic dermatomyositis-associated interstitial lung disease
JPRN-UMIN000032022Hamamatsu University School of Medicine66